Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Filings indexed 1,756 across all filing types
Latest filing 2025-01-24 Call Transcript
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter and nine months ended 31st December, 2024
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the audio recording of a conference call with analysts and investors about the financial results for the quarter and nine months ended December 31, 2024. It references a previous letter and provides a link to the audio recording on the company's website. The document does not contain the transcript itself, nor detailed financial data or analysis. It is essentially an announcement about the availability of the conference call recording. According to the classification rules, such a document is best classified as a Call Transcript (CT) related announcement, but since it only announces the recording and does not provide the transcript, it is not a transcript itself. However, the closest fitting category is Call Transcript (CT) because it pertains directly to the conference call content. Confidence is high due to explicit mention of the conference call and financial results period.
2025-01-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the audio recording of a conference call with analysts and investors about the financial results for the quarter and nine months ended December 31, 2024. It references a previous letter and provides a link to the audio recording on the company's website. The document does not contain the transcript itself, nor detailed financial data or analysis, but is an announcement about the availability of the conference call recording. According to the classification rules, such announcements about conference call recordings are best classified as Call Transcript (CT) if the transcript is included, but since this is only an announcement of the audio recording, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement related to financial results but does not contain the transcript or detailed financial data itself. The document length is short (1473 characters), supporting that it is an announcement rather than the full transcript or report.
2025-01-24 English
Press Release
Regulatory Filings
2025-01-24 English
Updates
Regulatory Filings
2025-01-24 English
Integrated Filing (Financial) for Q3 FY 2024-25.
Regulatory Filings
2025-01-24 English
Integrated Filing- Financial
Regulatory Filings
2025-01-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.